Navigation Links
Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Date:10/7/2010

mportant Sutent® (sunitinib malate) Safety Information

Hepatotoxicity has been observed in clinical trials and post-marketing experience.  This hepatotoxicity may be severe, and deaths have been reported.  It is recommended to monitor liver function tests before initiation of treatment, during each cycle of treatment, and as clinically indicated.  Sutent should be interrupted for Grade 3 or 4 drug-related hepatic adverse events and discontinued if there is no resolution.  Sutent should not be restarted if patients subsequently experience severe changes in liver function tests or have other signs and symptoms of liver failure.

Women of child bearing age who are (or become) pregnant during therapy should be informed of the potential for fetal harm while on Sutent.

Decreases in left ventricular ejection fraction (LVEF) to below the lower limit of normal (LLN) have been observed.  Patients with concomitant cardiac conditions should be carefully monitored for clinical signs and symptoms of congestive heart failure.  Patients should be monitored for hypertension and treated as needed with standard antihypertensive therapy.  Complete blood counts (CBCs) with platelet count and serum chemistries should be performed at the beginning of each treatment cycle for patients receiving treatment with Sutent.

The most common adverse reactions in GIST and RCC clinical trials were diarrhea, fatigue, asthenia, nausea, mucositis/stomatitis, anorexia, vomiting, hypertension, dyspepsia, abdominal pain, constipation, rash, hand-foot syndrome, skin discoloration, altered taste and bleeding.

For more information on Sutent including full prescribing information please visit www.pfizer.com.

About Aromasin® (exemestane tablets)

Aromasin is the only aromatase inhibitor indicated for sequential therapy in postmenopausal women with
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Mass. , Oct. 22, 2014 InVivo ... Cambridge, MA is revolutionizing spinal cord injury ... has been shown to outperform in tissue regrowth in ... the scaffold.  Made from an FDA approved polymer, the ... making it harmless to the human body. NVIV has ...
(Date:10/22/2014)... , Oct. 22, 2014 WHEN: Wednesday, October ... complimentary registration available at: http://bit.ly/1yStiU9 ... Vidyasekar and Visionary Innovation Research Group Senior ... electricity, self-assembling materials, nanobots and flexible electronics ... will transform our lives in the coming ...
(Date:10/22/2014)... -- Provectus Biopharmaceuticals, Inc. (NYSEMKT: PVCT) specializes in developing ... for cancer, is designed for injection into solid tumors ... focus is on melanoma, breast cancer and cancers of ... PV-10 as a therapy for metastatic melanoma, and of ... psoriasis. This summer, the Company signed ...
Breaking Medicine Technology:InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Provectus Biopharmaceuticals Looks at the Asian Markets: Analyst Coverage by Small Cap Traders 2
... 8, 2011 The Amerigroup Foundation recently announced that ... Partnership to benefit the Rockbridge Area Free Clinic. ... works to provide uninsured Virginians with access to medication ... access and distribute free bulk prescription medications to 20 ...
... BOTHELL, Wash., July 8, 2011 Cardiac Science ... ( AED s) and diagnostic cardiac monitoring ... Labor, and Welfare approved a new model of its ... Healthcare to distribute its AEDs in Japan. Japan-based Omron ...
Cached Medicine Technology:Amerigroup Foundation Presents Grant to Rx Partnership 2Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 2Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 3Cardiac Science Gains Japanese Regulatory Approval for Powerheart AED 4
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... Not getting the right amount of sleep might raise ... Those who sleep less or more than the ... more prone to developing the chronic condition, which causes ... concluded that duration and quality of sleep are key ... diseases. "Both short and long durations of sleep ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- October,s shorter, ... as seasonal affective disorder, according to an expert. ... SAD, may feel overly tired, lack motivation and even ... SAD can lead to suicide, said Dr. Angelos Halaris, ... neurosciences at Loyola University Chicago Stitch School of Medicine. ...
(Date:10/22/2014)... Isabel Healthcare will participate in ... Conference on October 22-24 in Las Vegas, NV. Jason ... panel discussion on Technology in Health Professions Education – ... diagnostic decision support tool and clinical education platform designed ... and clinical learners. The Isabel tools help clinicians broaden ...
(Date:10/22/2014)... The Louis W. Sullivan Institute ... distribute health information technology innovation to transform quality ... development of six key guiding principles of patient-centered ... These are an expansion of the Institute of ... is respectful of and responsive to individual patient ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2
... ... 251 Surgical Cap prints, Scrub Sacks, StethoSocks™, Medical Dental T-Shirts, Baseball Caps, Beanies, Tote ... ... hospitalgowns.com and surgicalcaps.com launches its winter fashion season with comfortable healthcare ...
... 12 For the fifth year in a row, HealthPlus ... by U.S. News & World Report/NCQA as among the nation,s ... America,s Best Health Insurance Plans, released today, names ... top 25 Medicare plans, nationwide. , Moreover, HealthPlus of ...
... Amilpar (Bovespa: AMIL3;,Bloomberg: AMIL3 BZ and APAR < GO >; ... results for the third quarter,of 2009. , ... thousand at the end of September 2009,2.7% up on 3Q08 and ... Operating Revenues totaled R$ 1,237.1 million in 3Q09, 8.4% up,year-on-year and ...
... Nov. 11 MedCath Corporation (Nasdaq: MDTH ), ... today announced it has received licensure by the Arizona ... Commission for its new 70-bed Hualapai Mountain Medical Center ... hospital, which also has shelled space for another 36 ...
... But men much more likely to leave than women if spouse ... Cancer can put an enormous strain on a marriage, and couples ... the patient. , In fact, the odds of separation or divorce ... one with the illness, a new study shows. , The researchers ...
... ... for people with disabilities and renews its commitment to leading the effort to reduce the ... ... the one year anniversary of the launch on November 7, 2008 of its employment and ...
Cached Medicine News:Health News:Surgicalcaps.com Introduces Surgical Scrub Sacks 2Health News:Surgicalcaps.com Introduces Surgical Scrub Sacks 3Health News:HealthPlus Named One of 'America's Best Health Insurance Plans' -- Again 2Health News:Amilpar - Revenues Grow 8% and Net Income Improves 28% in 3Q09 2Health News:MedCath Receives Licensure and Accreditation for New Hualapai Mountain Medical Center 2Health News:Cancer Can Strain Marriages to Breaking Point 2Health News:GettingHired.com Recognizes First Year Anniversary, Renews Commitment to Helping Lead the Effort to Reduce Employment Participation Gap for People with Disabilities 2Health News:GettingHired.com Recognizes First Year Anniversary, Renews Commitment to Helping Lead the Effort to Reduce Employment Participation Gap for People with Disabilities 3
2 tests on one meter. Glucose test for immediate glucose levels. GlucoProtein (Fructosamine) for overall control, average over prior 2-3 weeks. The Duet is the only hand held instrument to perform th...
... ICON®microALB is a qualitative immunoassay for ... of kidney disease. This albumin specific, CLIA ... mg/L and specificity of 95%, and gives ... stable viewing results up to 8 hours. ...
... here! LTF™ (Layered Thin Film) technology is ... that is easy to read, extremely precise ... credit card. What is Infectious Vaginitis? Infectious ... visit their physician. Vaginal discharge and odor ...
... Screen Tests are available in 14 configurations ... Designed using Microgenics Antibody Technology, the SureStep™ ... of care immunoassay targeted to detect MDMA ... and MDEA but no cross-reactivity to any ...
Medicine Products: